Aqur Biosciences, Inc.
StreetZero Signal 63
About Aqur Biosciences, Inc.
Aqur Biosciences, Inc. is a bioscience company dedicated to pioneering next-generation cardiovascular therapies. The company is developing an LDL-C lowering compound utilizing its proprietary next generation LDL-C reducing PCSK9 inhibitors. It has not developed or produced any products and is in preclinical stages, with statements noting it is not currently adequately capitalized.
LATEST FUNDINGPrivate Placement
$1.5M
Announced 2026-09-18
TOTAL RAISED$1,500,000
IN THE NEWS
EMPLOYEES—
FOUNDED—
HQWestlake Village, CA, USA
Industry
Pharmaceuticals
Tags
BioscienceCardiovascularPCSK9 InhibitorsPharmaceuticals
Investors
Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.
Key highlights
- Company focuses on next-generation PCSK9 inhibitors for LDL-C reduction.
- Included in DelveInsight’s 2025 PCSK9 Inhibitors Market report.
- Announced new brand identity reflecting strategic focus on cardiovascular therapies.
- Team includes experts with NIH funding history and Pfizer drug discovery experience.
- Emphasizes need for sufficient capital to advance preclinical pipeline.
Ask StreetZero about Aqur Biosciences, Inc.
Put our AI to work on this deal.
Similar companies
Other Pharmaceuticals deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account